報價延遲最少15分鐘:2025/05/30 12:59 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.53 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.28/-0.37
|
|
企業價值
55.48M
|
| 資產負債 |
|
每股賬面淨值
1.01
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/30 12:59 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. |